Biocitech: Mutabilis receives EUR four million of EU funding for its HIVINNOV project
Mutabilis announced that it has received EUR four million of European funding for the HIVINNOV project, which is aimed at developing new antiretrovirals against HIV.
The Mutabilis project, known as “Generation of a new class of antiretrovirals targeting HIV-cellular cofactors interactions”, or HIVINNOV, entails the development of new anti-HIV antiretrovirals up to the Phase IIa clinical trial stage. The particular feature of these new antiretrovirals is that they do not target the virus directly, as the majority of existing antiretrovirals do, but the interactions between the virus and its host, which are essential for the replication of the virus. The project, which will get under way in October when a launch meeting is to be held at the Biocitech science and technology park, is due to last three years and to receive total funding of EUR six million.
“The commission was apparently very impressed with the major advances we have made with the compounds we are developing, as well as the quality of the consortium and the research projects proposed,” said the scientific director of Mutabilis, Dr. Richard Benarous. “This success should encourage all the companies on the Biocitech campus to pay more attention and respond to European tenders that often give precedence to collaborations between innovative SMEs and European academic partners.”
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
